Mirtel (Mirtazapine)

Mirtazapine, the active ingredient in Mirtel, is a NaSSA (noradrenergic and specific serotonergic antidepressant) presented as an oral tablet for oral use. It is prescribed for the treatment of major depressive disorder in adult patients and may be part of a broader therapeutic plan.

GNH USA supplies Mirtel as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. Our distribution network adheres to stringent quality standards and regulatory requirements across multiple regions.

Mirtazapine is used primarily in the management of depressive disorders.

- Major depressive disorder: reduces depressive symptoms and improves functional outcomes. - Treatment‑resistant depression: may be considered when first‑line agents are insufficient. - Depressive episodes in bipolar disorder: used as adjunctive therapy to stabilize mood.

Mirtazapine may cause a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Sedation or somnolence. - Increased appetite leading to weight gain. - Dry mouth. - Constipation. - Dizziness. - Fatigue.

Serious or Rare Side Effects: - Agranulocytosis or severe neutropenia. - Significant hypotension or cardiovascular events. - Seizures. - Serotonin syndrome when combined with other serotonergic agents. - Suicidal ideation, especially early in treatment. - Hepatic dysfunction or jaundice.

Before initiating therapy, clinicians should consider several safety aspects. - Assess cardiovascular status: monitor blood pressure and heart rate. - Screen for bipolar disorder: risk of manic switch. - Evaluate hepatic function: dose adjustment may be needed. - Avoid abrupt discontinuation: taper to reduce withdrawal symptoms. - Pregnancy and lactation: use only if benefit outweighs risk. - Store at ambient temperature: keep in the original pack, protect from moisture and light.

Mirtazapine can interact with various medications, requiring careful management.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of severe serotonin syndrome. - Other serotonergic agents (SSRIs, SNRIs, tramadol): increased serotonin toxicity. - Carbamazepine: induces metabolism, reducing mirtazapine levels.

Moderate Interactions (Monitor Closely): - Alcohol: may enhance CNS depression and sedation. - CNS depressants (benzodiazepines, opioids): additive sedative effects. - Antihypertensive drugs: possible additive hypotensive effect.